HomeCompareSLRN vs PEP

SLRN vs PEP: Dividend Comparison 2026

SLRN yields 88.11% · PEP yields 3.63%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SLRN wins by $2.22M in total portfolio value
10 years
SLRN
SLRN
● Live price
88.11%
Share price
$2.27
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.37M
Annual income
$731,873.50
Full SLRN calculator →
PEP
PepsiCo Inc.
● Live price
3.63%
Share price
$156.82
Annual div
$5.69
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$141.9K
Annual income
$61,875.67
Full PEP calculator →

Portfolio growth — SLRN vs PEP

📍 SLRN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSLRNPEP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SLRN + PEP cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SLRN pays
PEP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SLRN
Annual income on $10K today (after 15% tax)
$7,488.99/yr
After 10yr DRIP, annual income (after tax)
$622,092.48/yr
PEP
Annual income on $10K today (after 15% tax)
$308.41/yr
After 10yr DRIP, annual income (after tax)
$52,594.32/yr
At 15% tax rate, SLRN beats the other by $569,498.16/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SLRN + PEP for your $10,000?

SLRN: 50%PEP: 50%
100% PEP50/50100% SLRN
Portfolio after 10yr
$1.25M
Annual income
$396,874.59/yr
Blended yield
31.65%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PEP right now

SLRN
Analyst Ratings
3
Buy
3
Hold
Consensus: Buy
Price Target
$10.50
+362.6% upside vs current
Range: $6.00 — $15.00
Altman Z
1.6
Piotroski
2/9
PEP
Analyst Ratings
1
Strong
15
Buy
27
Hold
1
Sell
Consensus: Hold
Price Target
$172.43
+10.0% upside vs current
Range: $156.00 — $191.00
Altman Z
3.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SLRN buys
0
PEP buys
0
No recent congressional trades found for SLRN or PEP in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSLRNPEP
Forward yield88.11%3.63%
Annual dividend / share$2.00$5.69
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$2.37M$141.9K
Annual income after 10y$731,873.50$61,875.67
Total dividends collected$2.08M$123.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold
Analyst price target$10.50$172.43

Year-by-year: SLRN vs PEP ($10,000, DRIP)

YearSLRN PortfolioSLRN Income/yrPEP PortfolioPEP Income/yrGap
1← crossover$19,511$8,810.57$10,849$509.42+$8.7KSLRN
2$36,942$16,065.36$11,969$750.47+$25.0KSLRN
3$67,956$28,428.44$13,500$1,124.14+$54.5KSLRN
4$121,587$48,874.33$15,680$1,721.66+$105.9KSLRN
5$211,824$81,725.42$18,929$2,715.34+$192.9KSLRN
6$359,715$133,063.84$24,023$4,450.80+$335.7KSLRN
7$596,079$211,183.71$32,510$7,669.92+$563.6KSLRN
8$964,860$327,055.60$47,709$14,093.60+$917.2KSLRN
9$1,527,165$494,764.27$77,415$28,083.48+$1.45MSLRN
10$2,365,940$731,873.50$141,922$61,875.67+$2.22MSLRN

SLRN vs PEP: Complete Analysis 2026

SLRNStock

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.

Full SLRN Calculator →

PEPConsumer Staples

PepsiCo, Inc. manufactures, markets, distributes, and sells various beverages and convenient foods worldwide. The company operates through seven segments: Frito-Lay North America; Quaker Foods North America; PepsiCo Beverages North America; Latin America; Europe; Africa, Middle East and South Asia; and Asia Pacific, Australia and New Zealand and China Region. It provides dips, cheese-flavored snacks, and spreads, as well as corn, potato, and tortilla chips; cereals, rice, pasta, mixes and syrups, granola bars, grits, oatmeal, rice cakes, simply granola, and side dishes; beverage concentrates, fountain syrups, and finished goods; ready-to-drink tea, coffee, and juices; dairy products; and sparkling water makers and related products. It serves wholesale and other distributors, foodservice customers, grocery stores, drug stores, convenience stores, discount/dollar stores, mass merchandisers, membership stores, hard discounters, e-commerce retailers and authorized independent bottlers, and others through a network of direct-store-delivery, customer warehouse, and distributor networks, as well as directly to consumers through e-commerce platforms and retailers. The company was founded in 1898 and is headquartered in Purchase, New York.

Full PEP Calculator →
📬

Get this SLRN vs PEP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SLRN vs SCHDSLRN vs JEPISLRN vs OSLRN vs KOSLRN vs MAINSLRN vs MOSLRN vs PMSLRN vs GIS

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.